StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
Shares of NASDAQ PULM opened at $2.02 on Thursday. The company has a 50 day simple moving average of $2.08 and a two-hundred day simple moving average of $2.02. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $2.75. The company has a market capitalization of $7.37 million, a price-to-earnings ratio of -0.68 and a beta of 1.00.
Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%. The company had revenue of $1.55 million for the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
See Also
- Five stocks we like better than Pulmatrix
- 3 Tickers Leading a Meme Stock Revival
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Insider Buying Explained: What Investors Need to Know
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- Ride Out The Recession With These Dividend Kings
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
